Literature DB >> 6258838

Effect of atenolol, metoprolol, and propranolol on isoproterenol-induced tremor and tachycardia in normal subjects.

E Perucca, H Pickles, A Richens.   

Abstract

The effect of single oral doses of atenolol (100 mg), metoprolol (100 mg), propranolol (40 mg), and placebo on exercise tachycardia and on heart rate and finger tremor responses to graded injections of isoproterenol was investigated in six normal subjects. Propranolol was more potent than atenolol and metoprolol in suppressing the increase in heart rate and tremor amplitude produced by isoproterenol, even though at the dose used it was the least effective of all three drugs in decreasing exercise tachycardia. Although these data are consistent with the hypothesis that the suppression of isoproterenol-induced tremor is mediated by antagonism of peripheral beta 2-adrenergic receptors, the possibility that a separate action other than beta-blockade may contribute to the tremorolytic action of propranolol cannot be excluded. The potential usefulness of examining the effect of beta-adrenoceptor blocking drugs on isoproterenol-induced tremor and tachycardia in cardioselectivity studies is discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6258838     DOI: 10.1038/clpt.1981.59

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  15 in total

1.  The effects of chronic dosing on the beta 1 and beta 2-adrenoceptor antagonism of betaxolol and atenolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Evaluation of the metabolic responses to inhaled salbutamol in the measurement of beta 2-adrenoceptor blockade.

Authors:  B J Lipworth; L C McFarlane; W J Coutie; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade.

Authors:  B J Lipworth; R A Brown; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

4.  Differential effects of alpha-adrenoceptor blockade on essential, physiological and isoprenaline-induced tremor: evidence for a central origin of essential tremor.

Authors:  B Abila; J F Wilson; R W Marshall; A Richens
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-10       Impact factor: 10.154

5.  Enhancement of physiological finger tremor by intravenous isoprenaline infusions in man: evaluation of its role in the assessment of beta-adrenoceptor antagonists.

Authors:  J M Arnold; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

6.  The effects of time and dose on the relative beta 1- and beta 2-adrenoceptor antagonism of betaxolol and atenolol.

Authors:  B J Lipworth; N A Irvine; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

7.  The tremorolytic action of beta-adrenoceptor blockers in essential, physiological and isoprenaline-induced tremor is mediated by beta-adrenoceptors located in a deep peripheral compartment.

Authors:  B Abila; J F Wilson; R W Marshall; A Richens
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

8.  Effect on finger tremor of withdrawal of long-term treatment with propranolol or atenolol.

Authors:  H J Wharrad; A T Birmingham; C G Wilson; E J Williams; J M Roland
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

9.  Contribution of the vagus to the haemodynamic responses following intravenous boluses of isoprenaline.

Authors:  J M Arnold; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

10.  Heart rate and blood pressure responses to intravenous boluses of isoprenaline in the presence of propranolol, practolol and atropine.

Authors:  J M Arnold; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1983-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.